



## Company Overview

CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar's founders of a novel group of naturally occurring mitochondrial-derived peptides within the mitochondrial genome that regulate metabolism and cell death, and whose biological activity declines with age. To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs. CohBar's efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, fibrotic diseases, cancer, acute respiratory distress syndrome (ARDS), type 2 diabetes, and cardiovascular and neurodegenerative diseases. The company's lead compound, CB4211, is in the Phase 1b stage of a Phase 1a/1b clinical trial for NASH and obesity. In addition, CohBar has four preclinical programs, two in cancer, one in fibrotic diseases and one in COVID-19 associated ARDS and type 2 diabetes.

## CohBar to Present at the Oppenheimer Fall Healthcare, Life Sciences, & MedTech Summit

Sep 10 2020, 4:05 PM EDT

## CohBar to Present at the H.C. Wainwright Annual Global Investment Conference

Sep 3 2020, 8:45 AM EDT

## CohBar Announces Closing of Public Offering of Common Stock and Warrants

Aug 28 2020, 4:05 PM EDT

## Stock Overview

Symbol	CWBR
Exchange	Nasdaq
Market Cap	60.57m
Last Price	\$1.045
52-Week	\$0.85 - \$4.25

## Investor Relations

Jordyn Tarazi  
Director, Investor Relations  
T: (650) 445-4441  
jordyn.tarazi@cohbar.com

09/17/2020 03:59 PM EDT

## Management Team

### Steven B. Engle

Chief Executive Officer, Director

### Kenneth C. Cundy, Ph.D.

Chief Scientific Officer

### Jeffrey F. Biunno, CPA, MBA

Chief Financial Officer, Secretary and Treasurer

## CohBar, Inc.

1455 Adams Drive  
Suite 2050  
Menlo Park, CA 94025

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.